Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Background of scattered on a plain blue background of many tablets in the form of a silhouette of the continents of the world 3d illustration

Drug pricing

Trump Wants To Bring Back International Drug Pricing Policy: Reuters

The so-called ‘Most Favored Nations’ rule would set drug pricing for Medicare in line with the prices paid by other nations, where drugs can be much cheaper.

April 23, 2025

2 min read

Annalee Armstrong

Two boxing gloves give a fist bump on a colored background. Collage art

Lung cancer

Summit’s Bispecific Beats Yet Another Cancer Med, Pressuring Keytruda’s ‘Supremacy’

Analysts at BMO Capital Markets expect Summit and Akeso’s HARMONi-6 readout to put some pressure on Merck and its blockbuster biologic Keytruda.

April 23, 2025

2 min read

Tristan Manalac

Mentorship concept, guidance and leadership, empathy and communication, face to face heads, negotiation and persuasion, common ground, emotional intelligence, vector flat illustration

Career Advice

You’re Right, But No One’s Listening: 3 Steps To Make Your Voice Impossible To Ignore

Just raising the alarm won’t drive action. Use these three steps to turn insights into solutions that leadership can’t ignore.

April 23, 2025

4 min read

Angela Justice

Pictured: Bristol Myers Squibb office in California

Neuropsychiatric disorders

‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos was unable to improve disease burden in non-obstructive hypertrophic cardiomyopathy.

April 23, 2025

2 min read

Tristan Manalac

Bridgewater, NJ, USA - August 23, 2022: Bausch Health US headquarters in Bridgewater, NJ, USA. Bausch Health Companies is a Canadian specialty pharmaceutical company.

Venture capitalists

Bausch Health Tussles With Activist Investor Carl Icahn After Popping Poison Pill

Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity from taking control of the company to the detriment of other shareholders.

April 23, 2025

1 min read

Tristan Manalac

Policy

RFK Considers Pulling COVID-19 From CDC’s Vaccine Guidelines for Children: Politico

Such a change would put the U.S. more in line with guidance in other countries and with the World Health Organization, which recommends one dose for children and adolescents only if they have comorbidities.

April 23, 2025

3 min read

Tristan Manalac

Contemporary art collage featuring a hand with a judicial hammer. Concept of Judge and Provost or Judgment Day

Legal

Lilly Takes Four Compounders to Court for Allegedly Producing Knockoff Tirzepatide

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, formally barring compounders from producing their knockoff versions of the drug.

April 23, 2025

2 min read

Tristan Manalac

Podcast

Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race

FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the agency and pharma industry; Roche and Regeneron jump on the U.S. manufacturing train as Trump’s tariffs loom; and Eli Lilly scores a big win for orforglipron while Novo Nordisk reveals it has applied for FDA approval of its oral semaglutide.

April 23, 2025

1 min read

Heather McKenzie